(Philadelphia,
PA) - Josep Dalmau, MD, PhD, has been named Associate
Professor in the Department of Neurology at the University
of Pennsylvania School of Medicine.
Prior to his appointment at Penn, Dr. Dalmau held faculty
positions at the University of Arkansas for Medical
Sciences, Memorial Sloan-Kettering Cancer Center, Cornell
University Medical College, and University Autonoma
of Barcelona in Spain. After earning his MD and PhD,
with honors, from the Autonoma University of Barcelona
School of Medicine, Dr. Dalmau completed a Residency
in Neurology at the University Hospital de la Sta. Cruz
y San Pablo, also in Spain, and fellowship training
in Neuro-Oncology at Memorial Sloan-Kettering in New
York.
Dr. Dalmau and his wife, Dr. Myrna Rosenfeld, were recruited
to Penn to develop the Division of Neuro-Oncology to
care for patients with malignant brain tumors and patients
with systemic cancer with develop neurologic problems.
They work closely with the Departments of Neurosurgery,
Radiation Oncology, and Medical Oncology and will be
holding clinical trials to test novel therapies for
malignant brain tumors. The Division of Neuro-Oncology
will offer clinical and research fellowship training
in Neuro-Oncology. To compliment their clinical activities,
Dr. Dalmau directs a National Institutes of Health (NIH)-supported
research lab that studies neurologic autoimmune disorders
that occur in patients with cancer called paraneoplastic
neurologic diseases.
Among his many professional medical affiliations, he
is an active member of the American Neurological Association,
the American Academy of Neurology, the American Society
of Clinical Oncology, American Association for Cancer
Research, and the Society of Neuro-oncology. In addition
to funding by the NIH, he has received several grants
and awards including the Charles A. Dana Neuroscience
Research Program Award and a Clinical Oncology Career
Development Award from the American Cancer Society.
Dr. Dalmau has contributed to many medical textbooks
and has had his research published in journals including
the New England Journal of Medicine, Journal of Clinical
Oncology, Brain Pathology, Annals of Neurology, Brain,
and Cell.
# # #
.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.